 Cellectar Biosciences, Inc. CLRB, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has appointed Dr. John Friend as chief medical officer, effective immediately. We are pleased to welcome John back to Cellectar to oversee CLR 131s late-stage oncology clinical development plans and FDA engagement for our adult and pediatric programs, said Jim Caruso, president and CEO of Cellectar Biosciences. Johns understanding and prior involvement with CLR 131 combined with his extensive experience in oncology drug development will prove invaluable to our overall development program and near-term pivotal study registration strategies. 